Year: 2025

– Total net sales of $145.4 million versus $147.2 million in prior year fourth quarter –– Net income of $2.1 million versus $3.6 million in prior year fourth quarter –– EBITDA of $7.3 million versus $9.9 million in prior year fourth quarter –– Board of Directors approves additional stock repurchase plan –– Provides full-year outlook – ST. PETERSBURG, Fla., March 11, 2025 (GLOBE NEWSWIRE) — Superior Group of Companies, Inc. (NASDAQ: SGC) (the “Company”), today announced its fourth quarter 2024 results. “For 2024, we grew sales and diluted EPS 4% and 35%, respectively, while strengthening our balance sheet and making strategic investments in our people, services, products and technology.  Capping the year, our fourth quarter results came in as expected, placing us within our full-year outlook ranges which were...

Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate for the treatment of aggressive large B-cell lymphoma (LBCL) Presented positive initial data from Phase 1 multi-center clinical trial of IMPT-314 in patients with aggressive LBCL in the 3rd line and later setting at the American Society of Hematology 2024 Annual Meeting Acceleration of development of IMPT-314 in LBCL; remain on track to initiate a pivotal trial in the 3rd line and later setting in mid-2025 and expect to initiate a pivotal trial in the 2nd line setting by early 2026 Advancing next-generation CAR T-cell product candidates with new targets and technologies; first IND for fully‑armed solid tumor product candidate expected in 2026 Cash, cash equivalents and marketable...

ROCKVILLE, Md., March 11, 2025 (GLOBE NEWSWIRE) — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its fourth quarter and full year ended December 31, 2024 financial results and initiated its 2025 guidance. Fourth Quarter and Full Year HighlightsTotal revenue of $8.7 million in the fourth quarter of 2024, a decrease of 45% over the fourth quarter of 2023. The decrease in total revenue was due to multiple one-time approval milestones in the fourth quarter of 2023. Core business revenue of $8.6 million in the fourth quarter of 2024, an increase of 20% over the fourth quarter of 2023. Strategic Platform License (SPL) Program-related revenue...

Increased Product Sales to $133 Million in 2024 Generated Pre-tax Operating Income and Net Income of $70 Million and $59 Million, Respectively, in 2024 Corporate Update Conference Call Today at 4:30 PM ETNEW YORK, March 11, 2025 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2024. “2024 was a year of strong financial performance and operational execution for SIGA in which we delivered $133 million in product sales and $70 million of pre-tax operating income. These results mark the second consecutive year of product revenue growth, reflecting SIGA’s continued financial strength,” stated Diem Nguyen, Chief Executive Officer. “As we enter 2025, we remain focused on durable growth and...

LEHI, Utah, March 11, 2025 (GLOBE NEWSWIRE) — Nature’s Sunshine Products, Inc. (Nasdaq: NATR) (“Nature’s Sunshine” and/or the “Company”), a leading manufacturer of high-quality herbal and nutritional supplements, reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Summary vs. Same Year-Ago QuarterNet sales were up 8.5% to $118.2 million compared to $108.9 million (up 10.0% in constant currency). GAAP net loss attributable to common shareholders of $0.3 million, or $(0.02) per diluted share, compared to net income of $9.0 million, or $0.46 per diluted share. Adjusted EBITDA up 6% to $10.3 million compared to $9.7 million.Full Year 2024 Financial Summary vs. 2023Net sales were up 2.0% to $454.4 million compared to $445.3 million (up 3.8% in constant currency). GAAP...

– Company generated quarterly sequential growth in YCANTH® dispensed applicator units of 12.3% in Q4’24 concurrent with significantly lower operating expenses – – Company reports positive quarterly revenue earlier than previously disclosed expectations, as new demand resulted in Company’s primary distribution partner ordering applicators of YCANTH during Q4’24 – – Late-stage pipeline continues to advance with programs in basal cell carcinoma (VP-315) and common warts (VP-102/YCANTH) – – Recently strengthened balance sheet with the November 2024 $42 million public offering – – Conference call scheduled for today at 4:30 pm ET – WEST CHESTER, Pa., March 11, 2025 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...

Announces Extension of Existing Share Repurchase Plan DENVER, March 11, 2025 (GLOBE NEWSWIRE) — Concrete Pumping Holdings, Inc. (Nasdaq: BBCP) (the “Company” or “CPH”), a leading provider of concrete pumping and waste management services in the U.S. and U.K., reported financial results for the first quarter ended January 31, 2025. First Quarter Fiscal Year 2025 Summary vs. First Quarter of Fiscal Year 2024 (where applicable)  ● Revenue of $86.4 million compared to $97.7 million.  ● Gross profit of $31.2 million compared to $33.3 million.  ● Income from operations of $3.5 million compared to $1.5 million.  ● Net loss of $2.6 million compared to a net loss of $3.8 million.  ● Net loss attributable to common shareholders was $3.1 million, or $(0.06) per diluted share, compared to a net loss of...

LITTLE ROCK, Ark., March 11, 2025 (GLOBE NEWSWIRE) — Westrock Coffee Company (Nasdaq: WEST) (“Westrock Coffee” or the “Company”) today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided its outlook for 2025 and 2026. Full Year 2024 Highlights1Consolidated ResultsNet sales were $850.7 million, a decrease of 1.6% Gross profit was $153.8 million, an increase of 10.0% Net loss was $80.3 million compared to a net loss of $34.6 million in fiscal 2023 Consolidated Adjusted EBITDA2 was $47.2 million and included $12.8 million of scale-up costs associated with our Conway Facility, compared to Consolidated Adjusted EBITDA of $45.1 million and no scale-up costs associated with our Conway FacilitySegment ResultsBeverage SolutionsNet sales were $659.4 million, a decrease of 8.8% Segment...

Date: Friday, March 14, 2025Time: 2:00 p.m. (Eastern Time) NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) — You are invited to participate in TerraForm Power Operating, LLC’s Fourth Quarter and Full-Year 2024 Results Webcast and Conference Call on March 14, 2025 at 2:00 p.m. (Eastern Time) to discuss results and current business initiatives with senior management. These results will be made available on our website at www.terraform.com in the form of audited consolidated financial statements for the years ended December 31, 2024 and 2023 under “Financials” prior to the webcast and conference call. Participants can join by conference call or webcast: Conference Call Please pre-register by conference call clicking here Upon registering, you will be emailed a dial-in number, direct passcode and unique PIN. This process will bypass the...

Invests $54.5 Million in AI Infrastructure in 2024 CoreWeave, Inc., Single Largest Initial Investment in Fund’s History, Files for IPO Net Asset Value of $6.68 Per Share as of December 31, 2024 NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) — SuRo Capital Corp. (“SuRo Capital”, the “Company”, “we”, “us”, and “our”) (Nasdaq: SSSS) today announced its financial results for the fourth quarter and fiscal year ended December 31, 2024. Net assets totaled approximately $157.6 million, or $6.68 per share, at December 31, 2024, as compared to $6.73 per share at September 30, 2024 and $7.99 per share at December 31, 2023. “Since inception, SuRo Capital has served as the public’s gateway to venture capital, offering unique access to some of the world’s most innovative and sought-after private companies before they become publicly traded....